Skip to main content
SpringerLink
Log in

JAK2 V617F due to a novel TG → CT mutation at nucleotides 1848–1849: diagnostic implication

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A uique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  PubMed  Google Scholar 

  2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  PubMed  Google Scholar 

  3. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  PubMed  Google Scholar 

  4. Levine RL, Waddleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  PubMed  Google Scholar 

  5. Tefferi A . Classification, diagnosis and management of myeloproliferative disorders in the JAK2 V617F era. Hematology Am Soc Hematol Educ Program 2006, 240–245.

    Article  Google Scholar 

  6. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycyrthemia vera. Blood 2006; 108: 1865–1867.

    Article  CAS  PubMed  Google Scholar 

  8. McClure R, Mai M, Lasho T . Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20: 168–171.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Pathology, Department of Pathology, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong

    C L P Wong, E S K Ma, C L N Wang & H Y Lam

  2. Specialist in Hematology and Hematological Oncology, St Paul's Hospital, Hong Kong, Hong Kong

    S Y Ma

Authors
  1. C L P Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E S K Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C L N Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Y Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Y Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E S K Ma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, C., Ma, E., Wang, C. et al. JAK2 V617F due to a novel TG → CT mutation at nucleotides 1848–1849: diagnostic implication. Leukemia 21, 1344–1346 (2007). https://doi.org/10.1038/sj.leu.2404654

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404654

  • Springer Nature Limited

This article is cited by

Search

Navigation